Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations

04-Jun-2015 - United Kingdom

In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years.  Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections. 

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Genetic clues to the causes of primary biliary cirrhosis - Researchers find new risk regions associated with primary biliary cirrhosis

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Genetic mutations that lead to macular degeneration blindness mapped by new research

Genetic mutations that lead to macular degeneration blindness mapped by new research

Barroso Commission recognises contribution of biotech crops to European competitiveness

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics

Atugen AG raises EUR 5 million venture funding for siRNA therapeutics program - siRNA therapeutics patent application published

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

Organon and Schering to continue research in male fertility control separately

A human enzyme (CD 39) targets the Achilles heel of sepsis - New research suggests that CD39 significantly improves survival of mice in severe sepsis

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million